Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations

Authors Castellan P, Marchioni M, Castellucci R, De Francesco P, Iantorno R, Schips L, Cindolo L

Received 31 August 2018

Accepted for publication 31 October 2018

Published 6 December 2018 Volume 2018:14 Pages 2341—2347

DOI https://doi.org/10.2147/TCRM.S159824

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh


Pietro Castellan,1 Michele Marchioni,2 Roberto Castellucci,1 Piergustavo De Francesco,2 Romina Iantorno,1 Luigi Schips,1,2 Luca Cindolo1

1Department of Urology, ASL02 Abruzzo, Chieti, Italy; 2Department of Urology, University “G. d’Annunzio”, Chieti, Italy

Abstract: In recent years, therapeutic advances, together with new medication sequences and combinations, have improved outcomes for prostate cancer. For a long time, androgen deprivation therapy (ADT) has been the standard of care for newly diagnosed, metastatic prostate cancer, first as a standalone therapy and then in combination with taxane-based regimens. More recently, the addition of abiraterone acetate to ADT to achieve complete androgen blockade has proven beneficial for the treatment of metastatic hormone-resistant prostate cancer and metastatic hormone-sensitive prostate cancer (mHSPC). In this review, we summarize recent findings on the early use of abiraterone in mHSPC and discuss survival benefits as reported in clinical trials. On the basis of existing data, abiraterone in combination with ADT could be considered a new standard of care for patients affected by mHSPC.

Keywords: prostate cancer, metastatic hormone-sensitive prostate cancer, androgen receptor, hormonal therapy, abiraterone acetate, prostate castration naïve

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]